Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
1
Favorite

Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial

Dow Jones2022-12-13

By Kathryn Hardison

Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma.

Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower.

Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results.

A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year.

The results were presented at the American Society of Hematology annual meeting in New Orleans.

Write to Kathryn Hardison at kathryn.hardison@wsj.com

(END) Dow Jones Newswires

December 12, 2022 12:52 ET (17:52 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment（1）

Nelliebear
·2022-12-14
👍
Reply
Like
Report

Most Discussed

7x24

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2291146287?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-12-13 01:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2291146287","market":"hk","top_or_hot":-1,"title":"Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HARP\">Harpoon Therapeutics Inc.</a> surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n</p>\n<p>\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n</p>\n<p>\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n</p>\n<p>\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n</p>\n<p>\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2022 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-13 01:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data ...</p>\n\n<a href=\"http://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2291146287","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2291146287","pubTimestamp":1670867520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CRCT":"Cricut, Inc.","BK4191":"家用电器","HARP":"Harpoon Therapeutics Inc.","BK4539":"次新股","TERN":"Terns Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Harpoon Therapeutics在复发/难治性多发性骨髓瘤试验的中期数据中的份额上升了90%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HARP":0.9,"CRCT":0.66,"TERN":0.66},"content_text":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n\n\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n\n\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n\n\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n\n\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n\n\n \n\n\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2022 12:52 ET (17:52 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9921919295,"gmtCreate":1670952878417,"gmtModify":1676538466259,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919295","repostId":2291146287,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}